✦ LIBER ✦

Disseminated autoimmune disease during levamisole treatment of nephrotic syndrome

✍ Scribed by G. Barbano; Fabrizio Ginevri; Gian M. Ghiggeri; Rosanna Gusmano

Publisher: Springer
Year: 1999
Tongue: English
Weight: 15 KB
Volume: 13
Category: Article
ISSN: 0931-041X
DOI: 10.1007/s004670050753

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Onset of leukaemia after levamisole trea

Onset of leukaemia after levamisole treatment for nephrotic syndrome

✍ F. E. Mackie; L. P. Roy; M. Stevens 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 207 KB

Treatment of partially corticosteroid-se

Treatment of partially corticosteroid-sensitive nephrotic syndrome with levamisole

✍ M. L. Mancini; S. Rinaldi; G. Rizzoni 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 77 KB

Long-term effects of levamisole treatmen

Long-term effects of levamisole treatment in childhood nephrotic syndrome

✍ Viktória Sümegi; Ibolya Haszon; Béla Iványi; Csaba Bereczki; Ferenc Papp; Sándor 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 134 KB

Vincristine treatment of nephrotic syndr

Vincristine treatment of nephrotic syndrome complicated by Kimura disease

✍ Annette Connelly; Harley R. Powell; Yuen F. Chan; David Fuller; Russell G. Taylo 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 153 KB

Autoimmune polyendocrine syndrome type 1

Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab

✍ Jonathan Popler; Mohammad Alimohammadi; Olle Kämpe; Frida Dalin; Megan K. Dishop 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 308 KB

## Abstract Autoimmune polyendocrine syndrome type 1 (APS‐1), also known as Autoimmune Polyendocrinopathy Candidiasis and Ectodermal Dysplasia (APECD) is a disorder caused by mutations in the autoimmune regulator (__AIRE__) gene. In some APS‐1 patients, significant pulmonary disease is observed. Au

Systematic evaluation of augmentation du

Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom Disease): Results from a prospective, multicenter study over 66 weeks

✍ Diego García-Borreguero; Birgit Högl; Luigi Ferini-Strambi; John Winkelman; Chri 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 915 KB

## Abstract The purpose of this study was to evaluate the incidence of augmentation over 66 weeks of treatment with ropinirole in patients with primary restless legs syndrome (RLS). Augmentation is the main complication of long‐term dopaminergic treatment of RLS. Despite widespread use of ropinirol